Prior PSMA PET-CT Imaging and Hounsfield Unit Impact on Tumor Yield and Success of Molecular Analyses from Bone Biopsies in Metastatic Prostate Cancer
Developing and optimizing targeted therapies in metastatic castration-resistant prostate cancer (mCRPC) necessitates molecular characterization. Obtaining sufficient tumor material for molecular characterization has been challenging. We aimed to identify clinical and imaging variables of imaging-gui...
Main Authors: | Minke Smits, Kamer Ekici, Samhita Pamidimarri Naga, Inge M. van Oort, Michiel J. P. Sedelaar, Jack A. Schalken, James Nagarajah, Tom W. J. Scheenen, Winald R. Gerritsen, Jurgen J. Fütterer, Niven Mehra |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-12-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/12/12/3756 |
Similar Items
-
Evaluation of <sup>68</sup>Ga-PSMA-11 PET-MRI in Patients with Advanced Prostate Cancer Receiving <sup>177</sup>Lu-PSMA-617 Therapy: A Radiomics Analysis
by: Wolfgang Roll, et al.
Published: (2021-07-01) -
Combined biology-guided radiotherapy and Lutetium PSMA theranostics treatment in metastatic castrate-resistant prostate cancer
by: Mathieu Gaudreault, et al.
Published: (2023-03-01) -
Upregulation of PSMA Expression by Enzalutamide in Patients with Advanced mCRPC
by: Florian Rosar, et al.
Published: (2022-03-01) -
Total Tumor Volume on <sup>18</sup>F-PSMA-1007 PET as Additional Imaging Biomarker in mCRPC Patients Undergoing PSMA-Targeted Alpha Therapy with <sup>225</sup>Ac-PSMA-I&T
by: Lena M. Unterrainer, et al.
Published: (2022-04-01) -
Advancements in PSMA ligand radiolabeling for diagnosis and treatment of prostate cancer: a systematic review
by: Yuanzhuo Yan, et al.
Published: (2024-03-01)